Table 1 Patient demographics and core baseline disease characteristics by treatment (pooled safety analysis set)
From: Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
CAD106 (2201) | CAD106 (2202) | CAD106 (total) | Placebo (total) | |
|---|---|---|---|---|
N = 22 | N = 25 | N = 47 | N = 11 | |
Sex, n (%) | ||||
Male | 14 (63.6) | 15 (60.0) | 29 (61.7) | 6 (54.5) |
Female | 8 (36.4) | 10 (40.0) | 18 (38.3) | 5 (45.5) |
Age (yr) | ||||
Mean (SD) | 65.6 (7.1) | 70.5 (8.7) | 68.2 (8.2) | 66.3 (6.9) |
Age group, n (%) | ||||
<65 yr | 10 (45.5) | 6 (24.0) | 16 (34.0) | 6 (54.5) |
65–75 yr | 10 (45.5) | 9 (36.0) | 19 (40.4) | 4 (36.4) |
>75 yr | 2 (9.1) | 10 (40.0) | 12 (25.5) | 1 (9.1) |
Race, n (%) | ||||
Caucasian | 22 (100.0) | 24 (96.0) | 46 (97.9) | 10 (90.9) |
Black | 0 (0.0) | 1 (4.0) | 1 (2.1) | 0 (0.0) |
Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (9.1) |
Years of education | ||||
Mean (SD) | 11.7 (2.7) | 14.2 (3.2) | 13.1 (3.2) | 12.2 (4.1) |
MMSE score at baseline | ||||
Mean (SD) | 23.1 (2.2) | 21.9 (1.9) | 22.5 (2.1) | 22.8 (2.3) |
Time since first symptom of AD was noticed by patient/caregiver (yr) | ||||
Mean (SD) | 5.4 (2.7) | 3.3 (2.2) | 4.3 (2.6) | 4.5 (1.8) |
Time since first symptom of AD was first diagnosed by physician (yr) | ||||
Mean (SD) | 2.0 (1.7) | 1.3 (1.3) | 1.6 (1.5) | 1.8 (1.3) |
ApoE4 carrier status, n (%)* | ||||
Missing | 2 (9.1) | 2 (8.0) | 4 (8.5) | 1 (9.1) |
Non-ApoE4 | 9 (40.9) | 3 (12.0) | 12 (25.5) | 1 (9.1) |
One ApoE4 | 8 (36.4) | 15 (60.0) | 23 (48.9) | 5 (45.5) |
Two ApoE4 | 3 (13.6) | 5 (20.0) | 8 (17.0) | 4 (36.4) |